Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.

Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A

Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.

Tefferi A, Strand JJ, Lasho TL, Elliott MA, Li CY, Mesa RA, Dewald GW

A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.

Mesa RA, Powell H, Lasho T, DeWald GW, McClure R, Tefferi A

Tipifarnib: farnesyl transferase inhibition at a crossroads.

Mesa RA

Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.

Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A

Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.

Mesa RA, Barosi G, Cervantes F, Reilly JT, Tefferi A

Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia.

Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA, Litzow MR

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D

Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia.

Mesa RA, Tefferi A

PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.

Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, Russell SJ